Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launched and acquired products, particularly in oncology and migraine therapies. CEO Albert Bourla credited a 22% increase in revenues from new products and acquisitions, highlighting the success of the Seagen integration and robust demand for Nurtec. Management also pointed to positive developments in legal settlements, which have improved clarity on post-2028 growth and cash flow. CFO David Denton emphasized ongoing cost management and targeted R&D investments as further contributors to the quarter’s outperformance.
Is now the time to buy PFE? Find out in our full research report (it’s free for active Edge members).
Pfizer (PFE) Q1 CY2026 Highlights:
- Revenue: $14.45 billion vs analyst estimates of $13.77 billion (5.4% year-on-year growth, 5% beat)
- Adjusted EPS: $0.75 vs analyst estimates of $0.72 (3.9% beat)
- Adjusted EBITDA: $5.99 billion vs analyst estimates of $6.33 billion (41.4% margin, 5.4% miss)
- The company reconfirmed its revenue guidance for the full year of $61 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $2.90 at the midpoint
- Operating Margin: 31.6%, down from 35.2% in the same quarter last year
- Organic Revenue rose 2% year on year
- Market Capitalization: $147.1 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Pfizer’s Q1 Earnings Call
- Vamil Divan (Guggenheim): Asked about upcoming obesity data disclosures at ADA. Chief Oncology Officer Chris Boshoff detailed that the company will present new data from the VESPER program and clarified which study results will be available.
- David Risinger (Leerink Partners): Asked about expectations for key oncology readouts and organizational restructuring. CEO Albert Bourla outlined recent changes to simplify business development, commercial, and strategy functions, while Boshoff discussed timelines for pivotal oncology studies.
- Chris Schott (JPMorgan): Inquired whether strong Q1 results could prompt guidance updates and about business development (BD) capacity. CFO David Denton confirmed no near-term guidance change but noted $7 billion in BD capacity for strategic transactions.
- Kerry Holford (Berenberg): Probed on Comirnaty vaccination rates and the impact of EU legal developments. International President Alexandre de Germay described stable European vaccination rates and positive outcomes from legal rulings.
- Asad Haider (Goldman Sachs): Sought detail on bridging the gap from loss of exclusivity events to future growth. Bourla explained the risk-adjusted pipeline approach and how the Vyndamax settlement reduces LOE-related revenue pressure.
Catalysts in Upcoming Quarters
Key factors to watch include (1) the pace and results of pivotal studies in obesity and oncology, (2) execution of cost savings and potential capital allocation actions following increased cash flow visibility, and (3) the impact of market dynamics on vaccine uptake and specialty drug launches. Progress in advancing the regulatory pipeline and business development activities will also be important to track.
Pfizer currently trades at $25.78, down from $26.30 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
